EGFR-specific nanoprobe biodistribution in mouse models

Nanotechnology offers a targeted approach to both imaging and treatment of cancer, the leading cause of death worldwide. Previous studies have found nanoparticles with a wide variety of coatings initiate an immune response leading to sequestration in the liver and spleen. In an effort to find a nanoparticle platform which does not elicit an immune response we created 43/44 nm gold or silver nanoparticles coated with biomolecules normally produced by the body, α-lipoic acid and the Epidermal Growth Factor (EGF), and have used mass spectroscopy to determine their biodistribution in mouse models, 24 hours following tail vein injection. Relative to controls, mouse EGF (mEGF) coated silver and gold nanoprobes are found at reduced levels in the liver and spleen. mEGF coated gold nanoprobes on the other hand do not appear to elicit any immune response, as they are found at background levels in these organs. As a result they should remain in circulation for longer and accumulate at high levels in tumors by the enhanced permeability retention (EPR) effect.

[1]  Manuela Semmler-Behnke,et al.  Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  C. Ong,et al.  Characterization, purification, and stability of gold nanoparticles. , 2010, Biomaterials.

[3]  T. Libermann,et al.  Expression of epidermal growth factor receptors in human brain tumors. , 1984, Cancer research.

[4]  Nicklas Raun Jacobsen,et al.  Biodistribution of gold nanoparticles in mouse lung following intratracheal instillation , 2009, Chemistry Central journal.

[5]  R. G. Freeman,et al.  Preparation and Characterization of Au Colloid Monolayers , 1995 .

[6]  A. Eisbruch,et al.  Analysis of the epidermal growth factor receptor gene in fresh human head and neck tumors. , 1987, Cancer research.

[7]  Yu Juan Zhang,et al.  Comparing the interparticle coupling effect on sensitivities of silver and gold nanoparticles , 2012 .

[8]  D. Meisel,et al.  Adsorption and surface-enhanced Raman of dyes on silver and gold sols , 1982 .

[9]  Aaron J. Smith,et al.  Aggregation of nanoparticles in endosomes and lysosomes produces surface-enhanced Raman spectroscopy , 2015 .

[10]  D. Neal,et al.  EPIDERMAL GROWTH-FACTOR RECEPTOR - A MARKER OF EARLY RELAPSE IN BREAST-CANCER AND TUMOR STAGE PROGRESSION IN BLADDER-CANCER - INTERACTIONS WITH NEU , 1989 .

[11]  A. Smith,et al.  Imaging EGFR distribution using surface-enhanced Raman spectroscopy , 2009, BiOS.

[12]  D. Appleton,et al.  Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer. , 1985, Journal of clinical pathology.

[13]  Michael A. Hupman,et al.  Development of a sensitive, stable and EGFR‐specific molecular imaging agent for surface enhanced Raman spectroscopy , 2015 .

[14]  J. Mendelsohn,et al.  Epidermal growth factor receptor expression in human lung carcinomas defined by a monoclonal antibody. , 1987, Journal of the National Cancer Institute.

[15]  B. Ozanne,et al.  The use of egf receptors and an alveolar differentiation marker to predict a poor survival in lung cancer , 1989 .

[16]  M. Bennett,et al.  EPIDERMAL-GROWTH-FACTOR RECEPTORS IN HUMAN BLADDER CANCER: COMPARISON OF INVASIVE AND SUPERFICIAL TUMOURS , 1985, The Lancet.

[17]  Keishiro Tomoda,et al.  Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size. , 2008, Colloids and surfaces. B, Biointerfaces.

[18]  G. Gibson,et al.  Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. , 1989, Cancer research.

[19]  G. Gibson,et al.  Epidermal growth factor receptors in non-small cell lung cancer. , 1987, British Journal of Cancer.

[20]  Leanne J. Lucas,et al.  Nanobiophotonics for molecular imaging of cancer: Au- and Ag-based Epidermal Growth Factor receptor (EGFR) specific nanoprobes , 2012, BiOS.

[21]  B. Gusterson,et al.  Over‐expression of the EGF receptor is a hallmark of squamous cell carcinomas , 1986, The Journal of pathology.

[22]  Pei-Xun Liu,et al.  Toxicologic effects of gold nanoparticles in vivo by different administration routes , 2010, International journal of nanomedicine.